전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved272 programs
CGTStandard DatabasestaleAbClonPhase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 59Status Recruiting
AntibodyLimited DatastaleUCB PharmaApproved

Certolizumab (Certolizumab)

Psoriasis; Atopic Dermatitis · Chronic Nonbacterial Osteomyelitis

#ChronicNonbacterialOsteomyelitis#Antibody#Approved#Popular#monoclonal-antibody+3
Trials 59Status Recruiting
CGTStandard DatabasestaleArtiva Biotherapeutics, Inc.Phase 2

Allogeneic NK cells (Allogeneic NK cells)

Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs) · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 58Status Recruiting
CGTStandard DatabasestaleKite, A Gilead CompanyPhase 2

Bridging Therapy (Bridging Therapy)

Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase2#Popular#cell-gene-therapy+4
Trials 58Status Discontinued
ADCLimited DatastaleMerck Sharp & Dohme LLCGovitecan in gynecologic ma…Phase 3

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan)

Non-small Cell Lung Cancer; Solid Tumors · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#Popular#antibody-drug-conjugate+5
Trials 57Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 56Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTLimited DatastaleShenzhen Hornetcorn Bio-technol…Preclinical

CIK cell therapy (CIK cell therapy)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#CGT#Preclinical#Popular#cell-gene-therapy+4
Trials 54Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleCRISPR Therapeutics AGPhase 1

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
CGTLimited DatastaleThe Leukemia and Lymphoma Socie…Phase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 53Status Active
AntibodyCurated CorestaleJanssenPhase 3

Amivantamab (Amivantamab)

Carcinoma, Non-Small-Cell Lung · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 51Status Recruiting
CGTLimited DatastaleHistograft Co., Ltd.Preclinical

"Histograft", a bone substitute based on octacalcium phosphate (OCP, "Histograft", a bone substitute based on octacalcium phosphate, "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene)

Non Union Fracture; Non-Union of Ankle Joint Without Infection · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 45Status Active
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 45Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#antibody-drug-conjugate#Carcinoma+4
Trials 41Status Recruiting
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 34Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#NonSmallCellLungCancer+1
Trials 32Status Recruiting
AntibodyLimited DatastaleETOP IBCSG Partners FoundationPhase 3

durvalumab (Imfinzi, Adjuvant durvalumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ETOP
Trials 31Status Recruiting
AntibodyLimited DatastaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Non-HodgkinLymphoma+1
Trials 30Status Active
AntibodyLimited DatastaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#monoclonal-antibody#RecurrentDiffuseLargeB-CellLymph+2
Trials 30Status Recruiting

2 / 14 pages

← PreviousNext →